Eurofins Announces the Successful Closing of the Biomnis Group Acquisition
October 15 2015 - 1:45AM
Business Wire
Regulatory News:
Following approval from regulatory bodies, as well as completion
of consultations with employee representatives, Eurofins Scientific
(Paris:ERF) (EUFI.PA), the global leader in bio-analytical testing,
and one of the world leaders in genomic services, announces the
successful closing of the transaction to acquire 100% of the
Biomnis Group on the 14th of October, 2015.
As communicated on the 22nd of June, the Group intends to offer
other prominent groups of laboratory networks in the clinical
biology testing market in France the option to co-invest in Biomnis
in the future. This planned partnership is in line with Eurofins’
intention to closely collaborate with all the stakeholders in the
French medical laboratories sector to support them in fulfilling
their objective of contributing to world-class patient care in
France.
Generating revenues of over EUR 220m in 2014, Biomnis is one of
the largest independent esoteric laboratories in Europe focusing on
specialty diagnostic testing, and should provide Eurofins a strong
platform on which to deploy the competencies in specialty clinical
diagnostic testing that the Group has obtained, and continues to
develop, at its recently-acquired laboratories in the US. In
return, Biomnis will have access to the full range of Eurofins’
growing esoteric testing portfolio to further develop its
leadership in specialty clinical diagnostic testing market in
France, and more widely in Europe.
As part of Eurofins’ plans to support Biomnis’ objective to
become the leading specialty clinical diagnostics testing provider
in Europe, its current leader, Dr. Charles Woler and the entire
Biomnis management team will remain with the company. Furthermore,
the Biomnis team is pleased to welcome Mr. François Cornu, a
seasoned biologist renowned in the French clinical biology market,
who will be joining as President of Biomnis specialty
laboratory.
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With 20,000 staff in around 200 laboratories across 38
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products, as well as for innovative clinical
diagnostic. The Group provides its customers with high-quality
services, accurate results on time and expert advice by its highly
qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients' increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151014006326/en/
Investor RelationsEurofins Scientific GroupPhone: +32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024